News | Atrial Fibrillation | May 13, 2019

Smartphones Used to Successfully Screen More than 60,000 for Atrial Fibrillation

Represents one of the largest population screening efforts for AF ever performed

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

May 13, 2019 — A digital screening for atrial fibrillation (AFib or AF) successfully monitored more than 60,000 participants from the general population in Belgium using only a smartphone. The results of the late-breaking DIGITAL-AF II study were presented at Heart Rhythm 2019, the Heart Rhythm Society's 40th annual Scientific Sessions.

The study demonstrated the feasibility of collecting data in a scalable, controlled and cost-effective way. The results of the trial produced a relevant yield of new AF patients without over-consuming healthcare resources. 

AF affects more than 33.5 million adults each year globally and this number is expected to continue to rise.[1] This means that the number of patients recommended to screen, aged 65 years and older, will reach an unprecedented volume resulting in unforeseen demands on the healthcare resources. Novel technologies are emerging, such as smartphone APPS that use pulse-plethysmography (PPG) through the camera that make it easier for patients to screen and collects digital results that physicians can track without a visit to the hospital.

All participants had a smartphone and gained access to the app (CE/FDA-cleared; FibriCheck by Qompium) by scanning a QR code distributed via pre-existing communication channels including newspapers throughout Belgium and were instructed to measure heart rhythm twice daily and when experiencing symptoms, for an eight-day monitoring period. After recording their symptoms, each measurement was classified as regular rhythm, possible AF, irregular rhythm or insufficient quality. To ensure high diagnostic accuracy, all irregular measurements were analyzed by medical technicians under supervision of cardiologists. After eight days, all participants received a report with a conclusion and a copy of their rhythm traces.

During the two-week trial, 62,821 participants were enrolled in the digital AF screening, and 61,730 participants completed the monitoring period resulting in a database of 588,282 60-second PPG-traces. Results revealed that 791 participants (or 1.3 percent) performed measurements indicative for AF. The average age of the AF group was 61.9 ± 10.9 years, and 75.9 percent was male. Within the AF group, 72 percent of patients did not experience symptoms. There were 210 patients (or 27 percent) with persistent AF, all detected on the first PPG-measurement. There were 581 patients (or 73 percent) that had paroxysmal AF, with 111 detected on the first PPG-measurement.

"It's fascinating to see the impact that PPG technology is having on clinical practice. Using digital tools in a very structured way enables us to outpace any other traditional methodology to screen or prescreen patients and guide them into an appropriate care pathway," said lead author Tine Proesmans, MASc, Mobile Health Unit, Hasselt University in Belgium. "Using digital technology only, we were able to reach a large population very quickly and collect clinically meaningful and actionable data, without the need for medical infrastructure. Patients also benefit by having the flexibility to take measurements anytime, anywhere, and at a fraction of the cost."

The results presented at Heart Rhythm 2019 build on the initial data set presented in 2018 at the ESC Congress and shows the feasibility of mass screening for a significantly larger, general patient population.

The authors of this study will continue with phase two of the trial and distribute follow-up questionnaires to the participants that will MAP the decision-making process of screening- positive participants and their physicians. They will also assess the impact of the screening at various time intervals after reporting. In future trials, they hope to expand their trial outside of Belgium and continue to increase the patient screening population.

All the HRS 2019 late-breaking studies 

Link to other HRS 2019 news

Reference:
1. Sumeet S. Chugh et al. Worldwide Epidemiology of Atrial Fibrillation. Circulation. 2014;129:837–847

Related Content

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Feature | Atrial Fibrillation | July 24, 2019
July 24, 2019 — Atrial fibrillation (AFib) is a common abnormal heart rhythm.
New Technology Improves Atrial Fibrillation Detection After Stroke
News | Atrial Fibrillation | July 19, 2019
A new method of evaluating irregular heartbeats outperformed the approach that’s currently used widely in stroke units...
An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vei
The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral
Aurigen Medical Atrial Fibrillation Device Wins ICI Innovation Award
News | Atrial Fibrillation | December 18, 2018
Irish medical device company AuriGen Medical won the prestigious Global Innovation Award at the International...

An example of the new generation of cardiac monitoring device that is replacing Holter monitoring is the Cardea Solo wearable sensor. The FDA-cleared device automatically analyzes data when the device is turned back into the physician's office and automatically produces a draft summary report. This technology can simplify the workflow by eliminating the need for third-party involvement.

Feature | Atrial Fibrillation | September 13, 2018
Rapid advances in technology to monitor atrial fibrillation (AF or Afib) are enabling clinicians to access real-time
Overlay Init